Downregulation of PHLPP expression contributes to hypoxia-induced resistance to chemotherapy in colon cancer cells

Molecular and Cellular Biology

Volumn 33, Issue 22, 2013, Pages 4594-4605

  Wen, Yang An ^a   Stevens, Payton D ^a   Gasser, Michael L ^b   Andrei, Romina ^b   Gao, Tianyan ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARBONATE DEHYDRATASE IX; CARFILZOMIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MESSENGER RNA; OXALIPLATIN; PACLITAXEL; PEPTIDASE; PHOSPHOPROTEIN PHOSPHATASE; PLECKSTRIN HOMOLOGY DOMAIN LEUCINE RICH REPEAT PROTEIN PHOSPHATASE 1; PLECKSTRIN HOMOLOGY DOMAIN LEUCINE RICH REPEAT PROTEIN PHOSPHATASE 2; RAPAMYCIN; TUBERIN; UBIQUITIN SPECIFIC PEPTIDASE 46; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIC CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; UBIQUITINATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; CELL LINE, TUMOR; COLON; COLONIC NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PROTEIN BIOSYNTHESIS; PROTEOLYSIS; TOR SERINE-THREONINE KINASES; UBIQUITINATION;

EID: 84887008822     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00695-13     Document Type: Article

References (39)

1. Lu X, Kang Y. 2010. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res. 16:5928-5935.
2. Rankin EB, Giaccia AJ. 2008. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 15:678-685.
3. Majmundar AJ, Wong WJ, Simon MC. 2010. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40:294-309.
4. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. 2001. Targeting of HIF-α to the von Hippel- Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472.
5. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen- dependent proteolysis. Nature 399:271-275.
6. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG, Jr. 2004. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18:2893-2904.
7. Wouters BG, van den Beucken T, Magagnin MG, Koritzinsky M, Fels D, Koumenis C. 2005. Control of the hypoxic response through regulation of mRNA translation. Semin. Cell Dev. Biol. 16:487-501.
8. Ma XM, Blenis J. 2009. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10:307-318.
9. Brown JM, Wilson WR. 2004. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4:437-447.
10. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, Dive C. 2004. Hypoxiamediated down-regulation of Bid and Bax in tumors occurs via hypoxiainducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol. Cell. Biol. 24:2875-2889.
11. Lin SC, Chien CW, Lee JC, Yeh YC, Hsu KF, Lai YY, Tsai SJ. 2011. Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells. J. Clin. Invest. 121:1905-1916.
12. Wilson WR, Hay MP. 2011. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11:393-410.
13. Brognard J, Newton AC. 2008. PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol. Metab. 19:223-230.
14. Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, Stein J, Stein GS, Iglehart JD, Shi Q, Pardee AB. 2010. MstI is an interacting protein that mediates PHLPPs' induced apoptosis. Mol. Cell 38:512-523.
15. Shimizu K, Mackenzie SM, Storm DR. 2010. SCOP/PHLPP and its functional role in the brain. Mol. Biosyst. 6:38-43.
16. Warfel NA, Newton AC. 2012. Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling. J. Biol. Chem. 287:3610-3616.
17. Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, Murn J, Navin N, Atwal GS, Sander C, Gerald WL, Cordon-Cardo C, Newton AC, Carver BS, Trotman LC. 2011. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 20:173-186.
18. Liu J, Weiss HL, Rychahou P, Jackson LN, Evers BM, Gao T. 2009. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene 28:994-1004.
19. Molina JR, Agarwal NK, Morales FC, Hayashi Y, Aldape KD, Cote G, Georgescu MM. 2012. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene 31:1264- 1274.
20. Nitsche C, Edderkaoui M, Moore RM, Eibl G, Kasahara N, Treger J, Grippo PJ, Mayerle J, Lerch MM, Gukovskaya AS. 2012. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology 142:377-387.e1-5. doi:10 .1053/j.gastro.2011.10.026.
21. Li X, Liu J, Gao T. 2009. β-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt. Mol. Cell. Biol. 29:6192- 6205.
22. Li X, Stevens PD, Yang H, Gulhati P, Wang W, Evers BM, Gao T. 2013. The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer. Oncogene 32:471-478.
23. Brognard J, Sierecki E, Gao T, Newton AC. 2007. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 25:917-931.
24. Gao T, Furnari F, Newton AC. 2005. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 18:13-24.
25. Liu J, Stevens PD, Gao T. 2011. mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J. Biol. Chem. 286:6510-6520.
26. Larson Y, Liu J, Stevens PD, Li X, Li J, Evers BM, Gao T. 2010. Tuberous sclerosis complex 2 (TSC2) regulates cell migration and polarity through activation of CDC42 and RAC1. J. Biol. Chem. 285:24987-24998.
27. Vaupel P, Mayer A. 2007. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26:225-239.
28. Imamura T, Kikuchi H, Herraiz MT, Park DY, Mizukami Y, Mino- Kenduson M, Lynch MP, Rueda BR, Benita Y, Xavier RJ, Chung DC. 2009. HIF-1α and HIF-2α have divergent roles in colon cancer. Int. J. Cancer 124:763-771.
29. Keith B, Johnson RS, Simon MC. 2012. HIF1αand HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12:9-22.
30. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L. 2009. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16:259-266.
31. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. 2008. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 22:239-251.
32. Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC. 2006. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 21:521-531.
33. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS, Ogino S. 2010. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am. J. Pathol. 176:2292-2301.
34. Yeung TM, Gandhi SC, Bodmer WF. 2011. Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells. Proc. Natl. Acad. Sci. U. S. A. 108:4382-4387.
35. Marshall J. 2005. The role of bevacizumab as first-line therapy for colon cancer. Semin. Oncol. 32:S43-S47.
36. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. 2012. A unifying model for mTORC1-mediated regulation ofmRNA translation. Nature 485:109-113.
37. Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC, Chandra A, Raval R, O'Brien ST, Maxwell PH. 2006. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 66:3567- 3575.
38. Cannito S, Novo E, Compagnone A, Valfre di Bonzo L, Busletta C, Zamara E, Paternostro C, Povero D, Bandino A, Bozzo F, Cravanzola C, Bravoco V, Colombatto S, Parola M. 2008. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 29:2267-2278.
39. Dibble CC, Manning BD. 2009. A molecular link between AKT regulation and chemotherapeutic response. Cancer Cell 16:178-180.